2022 Guide to Patient Support Services

Coherus BioSciences

Coherus COMPLETE Support Services

844-483-3692

Coherus BioSciences’ Coherus COMPLETE offers comprehensive reimbursement and support services for patients receiving treatment with Udenyca (pegfilgrastim-cbqv) who are unable to afford this medication. The program also offers provider coding and billing services to facilitate appropriate billing and reimbursement.

Coherus COMPLETE

Coherus COMPLETE provides several financial assistance options for patients who have been prescribed Udenyca.

Co-Pay Assistance Program

This program reduces out-of-pocket costs for eligible, commercially insured patients. Eligible patients may pay $0 for each dose of Udenyca, up to a maximum annual benefit of $15,000. Coverage and reimbursement for patients with commercial insurance will vary based on individual health plans. To qualify for the Coherus COMPLETE Co-Pay Assistance Program, patients must have commercial insurance and not be covered under Medicare, Medicaid, or any federal- or state-funded insurance.

Patient Assistance Program

Udenyca may be provided to eligible uninsured and underinsured patients. To qualify for the Coherus COMPLETE Patient Assistance Program, patients must not be insured or be underinsured with commercial or government-sponsored insurance.

Product Replacement Program

After a documented claims denial, this support program provides replacement Udenyca and helps eligible patients find alternative financial support through independent foundations. To qualify patients for the Coherus COMPLETE Product Replacement Program, a qualifying claims denial must be available. The provider must show that the approved process has been followed and documented.

Provider Portal and Payer Coverage Tool

Provider support services are available through the Provider Portal as well as through the Payer Coverage Tool, which together facilitate access to reimbursement specialists and information about state-specific treatment coverage. Reimbursement support services include:

  • Assistance with the verification of insurance and benefits details
  • Udenyca-specific coding, billing details, and claims appeal process
  • Prior authorization requirements and facilitation.

Application and Enrollment

For information on enrollment in Coherus COMPLETE services, call 844-483-3692 or e-mail This email address is being protected from spambots. You need JavaScript enabled to view it.. Information may also be requested online.

TABLE Coherus BioSciences Oncology Drug

Drug
Indication
Patient support programs

Drug
Udenyca (pegfilgrastim-cbqv)
Indication
Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)